Cargando…
Positive Impact of Home ERT for Mucopolysaccharidoses and Pompe Disease: The Lesson Learnt from the COVID-19 Pandemic
Objective: Patients with Lysosomal disorders (LSDs) are treated with regular infusions of enzyme replacement therapy (ERT). During the COVID-19 pandemic, home treatment was permitted. This study aimed at monitoring the patients’ compliance with home therapy and its effects on physical, psychological...
Autores principales: | Fiumara, Agata, Lanzafame, Giuseppina, Sapuppo, Annamaria, Arena, Alessia, Cirnigliaro, Lara, Barone, Rita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137846/ https://www.ncbi.nlm.nih.gov/pubmed/37108010 http://dx.doi.org/10.3390/healthcare11081176 |
Ejemplares similares
-
Enzyme replacement therapy (ERT) in pompe disease
por: Fiumara, Agata
Publicado: (2014) -
COVID-19 Pandemic Outbreak and its Psychological Impact on Patients with Rare Lysosomal Diseases
por: Fiumara, Agata, et al.
Publicado: (2020) -
S3.1 Are there ERT defined guidelines
for Pompe disease?
por: Toscano, Antonio, et al.
Publicado: (2011) -
Imaging findings of mucopolysaccharidoses: a pictorial review
por: Palmucci, Stefano, et al.
Publicado: (2013) -
Safety outcomes and patients’ preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond
por: Toscano, Antonio, et al.
Publicado: (2023)